The company said its Board of Directors appointed Abbas Hussain as a director on September 28, 2024, upon the recommendation of the Nominating and Corporate Governance Committee, effective October 2, 2024.

1. 01

   The company said its Board of Directors appointed Abbas Hussain as a director on September 28, 2024, upon the recommendation of the Nominating and Corporate Governance Committee, effective October 2, 2024.

2. 02

   The company said the size of the Board was set at 9 directors at the same time Hussain was appointed. It also said he will serve as a Class II director until the 2026 annual meeting of shareholders and was appointed to the Audit Committee.

3. 03

   The company said Hussain served as Chief Executive Officer of Vifor Pharma from 2021 to 2023, and held leadership roles at GlaxoSmithKline and Eli Lilly and Company.

4. 04

   The company said Hussain will receive a pro-rata portion of the Initial Grant and Annual Grant under the non-employee director compensation policy. It also said there are no separate arrangements related to his appointment and no transactions reportable under Item 404(a).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.